With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Key takeaways of Q3FY22 quarter & conference call highlights
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Subscribe To Our Newsletter & Stay Updated
